Author:
Cai Hongfu,Zhang Longfeng,Li Na,Chen Shen,Zheng Bin,Yang Jing,Weng Lizhu,Liu Mao-Bai
Funder
Fujian Provincial Department of Science & Technology
National Natural Science Foundation of China
Subject
Pharmacology (medical),Pharmacology
Reference24 articles.
1. Cancer statistics in China, 2015;Chen;CA Cancer J Clin,2016
2. Revisiting stage IIIB and IV non-small cell lung cancer: analysis of the surveillance, epidemiology, and end results data;William;Chest,2009
3. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer, Version 4.2018. Available at: https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf. Accessed April 26, 2018.
4. Guidelines of Chinese Society of Clinical Oncology (CSCO) Primary Lung Cancer. People’s medical publishing house;Chen;Chinese Society of Clinical Oncology,2018
5. Osimertinib as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer;Ramalingam;J Clin Oncol,2017